Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
Nature Medicine ( IF 58.7 ) Pub Date : 2024-10-16 , DOI: 10.1038/s41591-024-03348-1 Jing Pan, Yue Tan, Lingling Shan, Samuel Seery, Biping Deng, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Guang Hu, Taochao Tan, Ying Yuan, Zhenglong Tian, Fangrong Yan, Yajing Han, Jiecheng Zhang, Xiaoming Feng
更新日期：2024-10-17
Nature Medicine ( IF 58.7 ) Pub Date : 2024-10-16 , DOI: 10.1038/s41591-024-03348-1 Jing Pan, Yue Tan, Lingling Shan, Samuel Seery, Biping Deng, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Guang Hu, Taochao Tan, Ying Yuan, Zhenglong Tian, Fangrong Yan, Yajing Han, Jiecheng Zhang, Xiaoming Feng
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03282-2, published online 1 October 2024.
京公网安备 11010802027423号